BA3071
03 Jan 2023
Trial Summary
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Acronym:
BA3071
ACTRN/NCT /ethics:
NCT05180799
Scientific title:
A Phase 1/2 Study of BA3071
Sponsor / Cooperative group:
BioAtla, Inc.
Trial & Patient Characteristics
| Cancer Type | Solid cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I; Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Advanced |
| Anticipated Start Date | 2022-08-03 |
| Anticipated End Date | 2024-06-30 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead/Kate Penda |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Vineet Kwatra |
| Recruitment Status | Recruiting |